Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility

Chia-Hsuan Chou1,2, Ming-Ju Hsieh1,3,4, Chun-Yi Chuang5,6, Jen-Tsun Lin5,7, Chia-Ming Yeh8, Pao-Yu Tseng8, Shun-Fa Yang1,2, Mu-Kuan Chen1,8 and Chiao-Wen Lin9,10

1 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
2 Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan
3 Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan
4 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
5 School of Medicine, Chung Shan Medical University, Taichung, Taiwan
6 Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan
7 Division of Hematology and Oncology, Department of Medicine, Changhua Christian Hospital, Changhua, Taiwan
8 Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan
9 Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan
10 Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan

Correspondence to: Chiao-Wen Lin, email: cwlin@csmu.edu.tw
Mu-Kuan Chen, email: 53780@cch.org.tw

Keywords: FGFR4; polymorphism; OSCC; metastasis; betel quid chewing

Received: August 05, 2017  Accepted: September 23, 2017  Published: October 23, 2017

Copyright: Chou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Aberrations of the fibroblast growth factor receptor 4 (FGFR4) genomic region include amplification of FGFR4, activation of FGFR4 kinase domain mutations, and overexpression of FGFR4, which lead to sustained cell proliferation and contribute to tumor development. However, the association between FGFR4 single-nucleotide polymorphisms (SNPs) and risk of oral squamous cell carcinoma (OSCC) remains to be determined. We investigated the relationships between FGFR4 genetic polymorphisms, OSCC development and clinicopathological variables. We recruited a total of 955 patients with OSCC and 1191 controls. Four SNPs of FGFR4 (rs2011077, rs351855, rs7708357, and rs1966265) were examined using real-time polymerase chain reaction. We found that with the rs351855 GA genotype and a combination of the GA and AA genotypes exhibited a 1.431-fold (95% CI: 1.092–1.876) and 1.335-fold (95% CI: 1.033–1.725) higher risk of OSCC. However, patients with OSCC with a homozygous A/A genotype of FGFR4 rs351855 polymorphism had a lower risk of advanced stage OSCC (P = 0.0252). Furthermore, the patients with the FGFR4 rs351855/rs1966265 A-A haplotype had a 2.890-fold (95% CI: 2.257–3.700) higher risk of OSCC than the controls. Betel quid chewers with the A-A haplotype had a considerably higher risk (95% CI: 16.159–26.937) of OSCC than did betel quid nonchewers with other haplotypes. Moreover, an additional integrated in silico analysis proposed that rs351855 G allele variant to the A allele exhibited a relatively low energy of the transmembrane region. In conclusion, our results suggest that the FGFR4 rs351855 may play a role in susceptibility for OSCC development.
INTRODUCTION

Fibroblast growth factor receptors (FGFRs) modulate some crucial biological processes, such as cell proliferation, cell differentiation and tissue repair [1–3]. In humans, four FGFR family members (FGFR1 to FGFR4), which act as transmembrane tyrosine kinase receptors [4], and 18 fibroblast growth factors (FGFs), which are ligands for FGFRs, are observed. In cancers, aberrations of the FGFR4 genomic region include the amplification of FGFR4, activation of FGFR4 kinase domain mutations, and overexpression of FGFR4, which lead to sustained cell proliferation and contribute to tumor development [3].

Genetic variants of FGFR4 with several diseases have been documented. Gao et al observed that the A allele of rs351855 in FGFR4 was associated with a higher risk and worse prognosis of non-Hodgkin’s lymphoma than were other alleles [5]. Additional studies have revealed that four SNPs of FGFR4, namely rs2011077 (T/C), rs351855 (G/A, Gly388 to Arg388), rs7708357 (G/A), and rs1966265 (A/G, Ile10Val), might affect protein expression [6–8]. Our previous study revealed that FGFR4 rs351855 might be related with the risk of hepatocellular carcinoma (HCC) associated with liver cirrhosis and might increase the alpha-fetoprotein level in Taiwanese patients with HCC [9]. Another of our previous studies revealed that FGFR4 rs2011077 and rs1966265 were associated with the progression of normal cervical tissues to precancerous lesions in Taiwanese women, and FGFR4 rs351855 was associated with poor patient survival [10].

OSCC represents the most common oral neoplasm, and more than of 90% of all oral neoplasms are estimated to be OSCCs [11]. OSCC has the fourth highest incidence of malignancy in males of Taiwan [12]. Most cases of OSCC are diagnosed late [13]. At least 50% of patients with OSCC presented with late stage tumors during their first visit to medical centers in Taiwan, which resulted in a low overall 5-year survival rate [14]. In Taiwan, cigarette smoking, betel quid chewing, and alcohol consumption are the major risk factors for OSCC [15]. Betel quid chewing is a crucial risk factor because nearly 2.5 million people chew betel quid in Taiwan. Consequently, the incidence rate of OSCC in Taiwan is relatively high. However, only a few studies have investigated the associations between polymorphisms of FGFR4, environmental carcinogens and OSCC susceptibility, and the distribution of clinical features of OSCC in the Taiwanese male population. Therefore, we designed a case-control study to identify four FGFR4 gene polymorphisms (rs1966265, rs351855, rs2011077, and rs7708357; Figure 1A and 1B) and analyze their contribution to OSCCs as well as to determine the relationships between environmental factors and the clinicopathological characteristics of OSCC.

RESULTS

Population statistics and data of the participants

The statistical analysis of the demographic characteristics of the participants is shown in Table 1. In total, our data recruited 2146 participants in this case–control study, comprising 955 male patients with OSCC and 1191 controls. This study found significantly different distributions of betel quid chewing (p < 0.001), cigarette smoking (p < 0.001), and alcohol drinking (p < 0.001) between the patients with OSCC and controls.

FGFR4 gene polymorphism in patients with OSCC and controls

The genotypic and allelic frequencies of FGFR4 in patients with OSCC and controls are listed in Table 2. In the control group, the frequencies of the alleles of FGFR4 exhibited Hardy–Weinberg equilibrium (p>0.05). After adjustment for several variables, the data shown that participants with the rs351855 GA genotype and a combination of the GA and AA genotypes exhibited a 1.431-fold (95% CI: 1.092–1.876) and 1.335-fold (95% CI: 1.033–1.725) higher risk of OSCC, respectively, than wild-type homozygous participants.

Combined effects of environmental factors and FGFR4 gene polymorphism on OSCC

Our study determined the combined effect of environmental factors and FGFR4 gene SNPs on OSCC susceptibility (Table 3). In the study population, among 1479 smokers who were also betel quid chewers, participants with at least one C allele of rs2011077, one A allele of rs351855, or one G allele of rs1966265 exhibited 4.267-fold (95% CI: 2.855–6.376), 7.624-fold (95% CI: 4.839–12.011), 4.004-fold (95% CI: 1.931–8.300), and 4.354-fold (95% CI: 2.905–6.526) higher risks of OSCC, respectively, than smokers with the wild-type genes who were betel quid nonchewers.

Effects of the polymorphic genotypes of FGFR4 on the clinical status of OSCC

Furthermore, our study explored the effects of the polymorphic genotypes of FGFR4 on the clinicopathological status of OSCC, which includes TNM clinical staging, tumor size, lymph node involvement, and cell differentiation (Table 4). No significant associations were observed between the rs2011077, rs7708357, and rs1966265 gene polymorphisms and the clinicopathological status of OSCC. However, among the 955 patients with oral cancer, those who had a polymorphic rs351855 (A/A) gene received protection against developing an advanced clinical stage (stage
III/IV) of OSCC (OR: 0.648; 95% CI: 0.443–0.947) compared with patients with the rs351855 wild type after adjustment for several variables (adjusted OR: 0.637; 95% CI: 0.435–0.933).

Haplotype analysis of polymorphisms in FGFR4 in the susceptibility to OSCC

Our study used PHASE version 2.1 to reconstruct the common haplotypes. The haplotype frequencies of rs351855/rs1966265 among the study participants are presented in Table 5. When participants with the rs351855 G allele and rs1966265 A allele were selected as a reference group, participants with the G-G (AOR = 2.750; 95% CI: 2.150–3.516) and the A-A (adjusted OR = 2.890; 95% CI: 2.257–3.700) haplotypes were significantly associated with the risk of OSCC.

Combined effects of betel quid chewing and FGFR4 haplotypes on OSCC development

Our study further analyzed the relationship between the combined effect of betel quid chewing and the FGFR4 haplotypes on OSCC development (Table 6). Betel quid nonchewers with other haplotypes (G-A, G-G, and A-G) were considered the reference group. After adjustment for several variables, we observed that participants who were betel quid nonchewers with the A-A haplotype had a 1.960-fold (95% CI: 1.560–2.464) higher risk of OSCC than the reference group. Betel quid chewers with other haplotypes had a 15.394-fold (95% CI: 12.446–19.039) higher risk of OSCC than did the reference group. Overall, betel nut chewers with the A-A haplotype had the highest risk of OSCC development (AOR: 20.863; 95% CI: 16.159–26.937).

Functional connotation of the FGFR4 rs351855 locus

Our study also conducted a functional analysis of FGFR4 rs351855. The data obtained the FGFR4 rs351855 locus in the transmembrane domain from the Pfam database (Figure 2A and 2B). The Gly388Arg variation at the rs351855 locus is a highly conserved sequence across the human, chimp, mouse, and rat genomes (Figure 2C). Then, TMHMM Server v. 2.0 was used to predict of transmembrane helices in proteins. As shown in Figure 2D, the rs351855 G allele variant to the A allele exhibited a relatively low energy of the transmembrane region.

Association of expression of FGFR4 and clinicopathological characteristics in OSCC

To further support our findings, we evaluated FGFR4 expression by using The Cancer Genome Atlas (TCGA) Data Portal from Broad GDAC Firehose to determine whether FGFR4 was involved in the development of head and neck squamous cell carcinoma (HNSCC). We found that FGFR4 mRNA expression was higher in tumor tissues than in normal tissues in various
cancers (Figure 3A). Furthermore, we chose patients with OSCC from the HNSCC database and found that FGFR4 expression significantly increased in cancerous tissues compared with normal tissues (Figure 3B). Moreover, FGFR4 mRNA expression was also significantly higher in the OSCC tissue than in their corresponding noncancerous tissue (Figure 3C). Otherwise, advanced clinical stage (stage III/IV) of OSCC patients had significantly higher expression of FGFR4 than stage I/II (Figure 3D). The relative FGFR4 mRNA level was significantly higher in > T2 than in ≤ T2 (Figure 3E).

**DISCUSSION**

In this study, we found that patients with FGFR4 SNP rs351855 with heterozygous GA and a combination of rs351855 GA and AA had an increased risk of OSCC. Moreover, the combined effect of environmental factors and FGFR4 polymorphisms significantly increased the risk of OSCC. Notably, patients with FGFR4 SNP rs351855 with homozygous AA were less likely to develop stage III or IV cancers. We further observed that the combination of betel quid chewing and FGFR4 haplotype A-A had the highest risk of OSCC.

| Variable                     | Controls(N=1191) | Patients(N=955) | p Value |
|------------------------------|------------------|-----------------|---------|
| Age (yrs)                    | Mean ± S.D.      | Mean ± S.D.     | p=0.068 |
|                              | 53.92 ± 10.03    | 54.76 ± 11.01   |         |
| Betel quid chewing           |                  |                 |         |
| No                           | 992 (83.3%)      | 188 (19.7%)     |         |
| Yes                          | 199 (16.7%)      | 767 (80.3%)     | p <0.001* |
| Cigarette smoking            |                  |                 |         |
| No                           | 558 (46.9%)      | 109 (11.4%)     |         |
| Yes                          | 633 (53.1%)      | 846 (88.6%)     | p <0.001* |
| Alcohol drinking             |                  |                 |         |
| No                           | 954 (80.1%)      | 424 (44.4%)     |         |
| Yes                          | 237 (19.9%)      | 531 (55.6%)     | p <0.001* |
| Stage                        |                  |                 |         |
| I+II                         | 467 (48.9%)      |                 |         |
| III+IV                       | 488 (51.1%)      |                 |         |
| Tumor T status               |                  |                 |         |
| T1+T2                        | 551 (57.7%)      |                 |         |
| T3+T4                        | 404 (42.3%)      |                 |         |
| Lymph node status            |                  |                 |         |
| N0                           | 648 (67.9%)      |                 |         |
| N1+N2+N3                     | 307 (32.1%)      |                 |         |
| Metastasis                   |                  |                 |         |
| M0                           | 944 (98.9%)      |                 |         |
| M1                           | 11 (1.1%)        |                 |         |
| Cell differentiation         |                  |                 |         |
| Well differentiated          | 151 (15.8%)      |                 |         |
| Moderately or poorly         | 804 (84.2%)      |                 |         |
| differentiated               |                  |                 |         |

Mann-Whitney U test or Fisher’s exact test was used between healthy controls and patients with oral cancer. * p value < 0.05 as statistically significant.
Dysregulation of FGFR4 activity has been observed in human epithelial carcinomas including head and neck, thyroid, breast, hepatocellular, and prostate tumors [16, 17]. A study showed that during treatment with doxorubicin or cyclophosphamide, the aberrant expression of FGFR4 in cancer cells causes reduced apoptosis sensitivity [18]. The previous study showed that overexpression of FGFR4 is significantly associated with a high clinical stage and tumor grade as well as poor patient survival in prostate cancer [19]. Overexpression of FGFR4 has been associated with resistance to chemotherapy in patients with breast cancer [18]. However, little information is available on the role of FGFR4 in OSCC. In the present study, we observed that FGFR4 rs351855 G/A (Gly388Arg) polymorphisms were significantly associated with susceptibility to OSCC (Table 2: Genotyping and allele frequency of FGFR4 single nucleotide polymorphism (SNP) in oral cancer and normal controls).

Dysregulation of FGFR4 activity has been observed in human epithelial carcinomas including head and neck, thyroid, breast, hepatocellular, and prostate tumors [16, 17]. A study showed that during treatment with doxorubicin or cyclophosphamide, the aberrant expression of FGFR4 in cancer cells causes reduced apoptosis sensitivity [18]. The previous study showed that overexpression of FGFR4 is significantly associated with a high clinical stage and tumor grade as well as poor patient survival in prostate cancer [19]. Overexpression of FGFR4 has been associated with resistance to chemotherapy in patients with breast cancer [18]. However, little information is available on the role of FGFR4 in OSCC. In the present study, we observed that FGFR4 rs351855 G/A (Gly388Arg) polymorphisms were significantly associated with susceptibility to OSCC (Table 2).

| Variable | Controls N=1191 (%) | Patients N=955 (%) | AOR (95% CI) | p Value       |
|----------|---------------------|-------------------|--------------|---------------|
| rs2011077 |                     |                   |              |               |
| TT       | 326 (27.4%)         | 236 (24.7%)       | 1.000 (reference) |               |
| TC       | 577 (48.5%)         | 509 (53.3%)       | 1.188 (0.907-1.557) | 0.210         |
| CC       | 288 (24.1%)         | 210 (22.0%)       | 0.986 (0.716-1.359) | 0.933         |
| TC+CC    | 865 (72.6%)         | 719 (75.3%)       | 1.121 (0.868-1.448) | 0.380         |
| T allele | 1229 (51.6%)        | 981 (51.4%)       | 1.000 (reference) |               |
| C allele | 1153 (48.4%)        | 929 (48.6%)       | 0.998 (0.852-1.170) | 0.985         |

rs351855

| Variable | Controls N=1191 (%) | Patients N=955 (%) | AOR (95% CI) | p Value       |
|----------|---------------------|-------------------|--------------|---------------|
| GG       | 334 (28.0%)         | 225 (23.5%)       | 1.000 (reference) |               |
| GA       | 596 (50.0%)         | 524 (54.9%)       | 1.431 (1.092-1.876) | 0.009*        |
| AA       | 261 (22.0%)         | 206 (21.6%)       | 1.136 (0.821-1.572) | 0.443         |
| GA+AA    | 857 (72.0%)         | 730 (76.5%)       | 1.335 (1.033-1.725) | 0.027*        |
| G allele | 1264 (53.1%)        | 974 (51.0%)       | 1.000 (reference) |               |
| A allele | 1118 (46.9%)        | 936 (49.0%)       | 1.076 (0.918-1.260) | 0.367         |

rs7708357

| Variable | Controls N=1191 (%) | Patients N=955 (%) | AOR (95% CI) | p Value       |
|----------|---------------------|-------------------|--------------|---------------|
| GG       | 1167 (98.0%)        | 932 (97.6%)       | 1.000 (reference) |               |
| GA       | 23 (1.9%)           | 22 (2.3%)         | 1.327 (0.624-2.820) | 0.462         |
| AA       | 1 (0.1%)            | 1 (0.1%)          | 0.647 (0.022-18.961) | 0.800         |
| AG+AA    | 24 (2.0%)           | 23 (2.4%)         | 1.283 (0.614-2.683) | 0.507         |
| G allele | 2357 (98.9%)        | 1886 (98.7%)      | 1.000 (reference) |               |
| A allele | 25 (1.1%)           | 24 (1.3%)         | 1.241 (0.606-2.542) | 0.555         |

rs1966265

| Variable | Controls N=1191 (%) | Patients N=955 (%) | AOR (95% CI) | p Value       |
|----------|---------------------|-------------------|--------------|---------------|
| AA       | 326 (27.4%)         | 228 (23.9%)       | 1.000 (reference) |               |
| AG       | 580 (48.7%)         | 514 (53.8%)       | 1.227 (0.936-1.610) | 0.139         |
| GG       | 285 (23.9%)         | 213 (22.3%)       | 1.020 (0.739-1.408) | 0.905         |
| AG+GG    | 865 (72.6%)         | 727 (76.1%)       | 1.159 (0.896-1.499) | 0.260         |
| A allele | 1232 (51.7%)        | 970 (50.8%)       | 1.000 (reference) |               |
| G allele | 1150 (48.3%)        | 940 (49.2%)       | 1.015 (0.866-1.189) | 0.857         |

The adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) were estimated by multiple logistic regression models after controlling for betel quid chewing, cigarette smoking and alcohol drinking.
2). Heinzle et al [20] demonstrated that among patients with colorectal cancer, \textit{FGFR4} A allele carriers had a five-fold higher risk of tumors that were stage II or higher. Chen et al [21] reported that patients with the \textit{FGFR4} SNP rs351855 AA or AG genotype exhibited a poorer biochemical recurrence-free survival than did those with the GG genotype. Therefore, the SNP rs351855 of \textit{FGFR4} polymorphism might provide a basis for surveillance programs. Moreover, the interaction between the \textit{FGFR4} polymorphisms investigated and environmental factor was significant (betel nut chewing and tobacco use) and was associated with a high incidence of OSCC development.

### Table 3: Associations of the combined effect of \textit{FGFR4} gene polymorphisms and betel quid chewing with the susceptibility to oral cancer among 1479 smokers

| Variable | Controls \(n=633\) (%) | Patients \(n=846\) (%) | OR (95% CI) | p Value | AOR (95% CI) | p Value |
|----------|------------------------|------------------------|-------------|---------|-------------|---------|
| rs2011077 |                        |                        |             |         |             |         |
| ^aTT genotype & non-betel quid chewing | 111 (17.5%) | 39 (4.6%) | 1.00 (reference) | 1.000 (reference) | | |
| ^bTC or CC genotype or betel quid chewing | 171 (27.0%) | 189 (22.3%) | 3.146 (2.068-4.785) | \(p<0.001^*\) | 2.684 (1.736-4.149) | \(p<0.001^*\) |
| ^cTC or CC genotype with betel quid chewing | 351 (55.5%) | 618 (73.1%) | 5.011 (3.401-7.384) | \(p<0.001^*\) | 4.267 (2.855-6.376) | \(p<0.001^*\) |
| rs351855 |                        |                        |             |         |             |         |
| ^aGG genotype & non-betel quid chewing | 127 (20.1%) | 26 (3.1%) | 1.00 (reference) | 1.000 (reference) | | |
| ^bGA or AA genotype or betel quid chewing | 147 (23.2%) | 199 (23.5%) | 6.612 (4.121-10.067) | \(p<0.001^*\) | 5.581 (3.427-9.091) | \(p<0.001^*\) |
| ^cGA or AA genotype with betel quid chewing | 359 (56.7%) | 621 (73.4%) | 8.449 (5.433-13.137) | \(p<0.001^*\) | 7.624 (4.839-12.011) | \(p<0.001^*\) |
| rs7708357 |                        |                        |             |         |             |         |
| ^aGG genotype & non-betel quid chewing | 437 (69.0%) | 118 (14.0%) | 1.00 (reference) | 1.000 (reference) | | |
| ^bGA or AA genotype or betel quid chewing | 181 (28.6%) | 710 (83.9%) | 14.527 (11.193-18.854) | \(p<0.001^*\) | 12.137 (9.303-15.834) | \(p<0.001^*\) |
| ^cGA or AA genotype with betel quid chewing | 15 (2.4%) | 18 (2.1%) | 4.444 (2.175-9.082) | \(p<0.001^*\) | 4.004 (1.931-8.300) | \(p<0.001^*\) |
| rs1966265 |                        |                        |             |         |             |         |
| ^aAA genotype & non-betel quid chewing | 111 (17.5%) | 38 (4.5%) | 1.00 (reference) | 1.000 (reference) | | |
| ^bAG or GG genotype or betel quid chewing | 168 (26.5%) | 183 (21.6%) | 3.182 (2.083-4.861) | \(p<0.001^*\) | 2.726 (1.756-4.232) | \(p<0.001^*\) |
| ^cAG or GG genotype with betel quid chewing | 354 (56.0%) | 625 (73.9%) | 5.157 (3.489-7.623) | \(p<0.001^*\) | 4.354 (2.905-6.526) | \(p<0.001^*\) |

The adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) were estimated by multiple logistic regression models after controlling for alcohol drinking. p values were adjusted for multiple comparisons by applying the Bonferroni correction.
These results suggest that FGFR4 polymorphisms exhibit synergistic effects with betel nut chewing and tobacco smoking, on susceptibility to OSCC.

The present study revealed the protective role of FGFR4 rs351855 AA genotype against developing an advanced clinical stage (stage III/IV); OR: 0.648; 95% CI: 0.443–0.947) cancer (Table 4). However, Sheu et al [9] observed that patients with HCC carrying at least one A genotype (GA and AA) of the FGFR4 rs351855 polymorphism may have an increased risk of liver cirrhosis. In patients with OSCC, Choi et al [22] demonstrated that with the FGFR4 allele Arg/Arg or Arg/Gly at amino acid 388 were associated with advanced N stage (pathologic N2+N3) when compared with a Gly allele-carrying group. In patients with HNSCC, Streit et al [23] revealed that high expression levels of FGFR4 and the Arg388 allele were associated with poor clinical outcomes. However, Ansell et al [24] reported contradictory results; they found that patients carrying the FGFR4 rs351855 Gly allele had a significantly higher risk of HNSCC. However, the opposite results from different studies on the same cancer merit further investigation.

Betel quid chewing has been established as a critical determinant of OSCC [12, 25].

| FGFR4 rs351855 | Clinical stage | OR (95% CI) | p Value | AOR (95% CI)* | p Value |
|----------------|----------------|-------------|---------|---------------|---------|
|                | Stage I/II (n=467) | Stage III/IV (n=488) |         |               |         |
| GG             | 98 (21.0%) | 127 (26.0%) | 1.000 (reference) | 1.000 (reference) |         |
| GA             | 257 (55.0%) | 267 (54.7%) | 0.802 (0.585-1.098) | p=0.168 | 0.797 (0.581-1.093) | p=0.159 |
| AA             | 112 (24.0%) | 94 (19.3%) | 0.648 (0.443-0.947) | p=0.025* | 0.637 (0.435-0.933) | p=0.021* |

| FGFR4 rs351855 | Tumor size | OR (95% CI) | p Value | AOR (95% CI)* | p Value |
|----------------|------------|-------------|---------|---------------|---------|
|                | <T2 (n=551) | > T2 (n=404) |         |               |         |
| GG             | 122 (22.1%) | 103 (25.5%) | 1.000 (reference) | 1.000 (reference) |         |
| GA             | 304 (55.2%) | 220 (54.5%) | 0.857 (0.626-1.174) | p=0.337 | 0.860 (0.628-1.178) | p=0.348 |
| AA             | 125 (22.7%) | 81 (20.0%) | 0.768 (0.523-1.126) | p=0.176 | 0.767 (0.522-1.126) | p=0.175 |

| FGFR4 rs351855 | Lymph node metastasis | OR (95% CI) | p Value | AOR (95% CI)* | p Value |
|----------------|------------------------|-------------|---------|---------------|---------|
|                | No (n=648) | Yes (n=307) |         |               |         |
| GG             | 148 (22.8%) | 77 (25.1%) | 1.000 (reference) | 1.000 (reference) |         |
| GA             | 353 (54.5%) | 171 (55.7%) | 0.931 (0.669-1.296) | p=0.672 | 0.928 (0.666-1.292) | p=0.658 |
| AA             | 147 (22.7%) | 59 (19.2%) | 0.771 (0.513-1.161) | p=0.213 | 0.765 (0.508-1.153) | p=0.201 |

| FGFR4 rs351855 | Metastasis | OR (95% CI) | p Value | AOR (95% CI)* | p Value |
|----------------|------------|-------------|---------|---------------|---------|
|                | M0 (n=944) | M1 (n=11) |         |               |         |
| GG             | 221 (23.4%) | 4 (36.4%) | 1.000 (reference) | 1.000 (reference) |         |
| GA             | 520 (55.1%) | 4 (36.4%) | 0.425 (0.105-1.715) | p=0.229 | 0.415 (0.102-1.680) | p=0.218 |
| AA             | 203 (21.5%) | 3 (27.2%) | 0.816 (0.181-3.692) | p=0.792 | 0.783 (0.172-3.559) | p=0.751 |

| FGFR4 rs351855 | Cell differentiation | OR (95% CI) | p Value | AOR (95% CI)* | p Value |
|----------------|----------------------|-------------|---------|---------------|---------|
|                | Well (n=151) | Moderate/poor (n=804) |         |               |         |
| GG             | 33 (21.9%) | 192 (23.9%) | 1.000 (reference) | 1.000 (reference) |         |
| GA             | 87 (57.6%) | 437 (54.4%) | 0.863 (0.559-1.334) | p=0.580 | 0.865 (0.559-1.338) | p=0.515 |
| AA             | 31 (20.5%) | 175 (21.7%) | 0.970 (0.570-1.651) | p=0.911 | 0.982 (0.577-1.674) | p=0.948 |

* Adjusting for the effects of betel quid chewing, cigarette smoking and alcohol drinking.
has resulted in a high incidence rate of OSCC in Taiwan [12]. Arecoline, which is a major component of areca nut, can produce 3-methyl nitrosamine propionitrile, a potent carcinogen, and safrole-like DNA adducts that have been shown to be genotoxic and mutagenic [26]. Several studies have reported that the ingredients of betel quid are correlated with carcinogenic effects and tumor promotion [27–31]. In the present study, we assessed the combined effects of betel quid chewing and \( \text{FGFR4} \) haplotypes among patients with OSCC. Participants who were betel nut chewers and had a high-risk haplotype were at a higher risk of OSCC than were those who were either betel nut chewers or had the high-risk haplotype. OSCC is etiologically related to betel nut chewing, which can trigger and aggravate the risk of OSCC.

When the rs351855 A allele of \( \text{FGFR4} \) polymorphism was substituted with the G allele, lower transmembrane domain energy was observed (Figure 2D). Bange et al [32] and Morimoto et al [33] have demonstrated that the Arg\(^{388}\) allele of \( \text{FGFR4} \) polymorphism in the transmembrane domain is associated with poor prognosis in breast cancer, colon cancer and high-grade soft-tissue sarcoma, respectively. Besides, a study found that the \( \text{FGFR4-R388} \) allele was linked to poor cancer prognosis and this risk variant enhanced pericellular ECM degradation by membrane type 1 matrix metalloproteinase (MT1-MMP) in a polarized manner, which resulted in rapid tumor cell invasion in collagen [34]. The T-A haplotype is a key factor in the course of the OSCC progression and in the synergistic effects with environmental factors, such as betel nut chewing, that intensify the risk of OSCC.

We further investigated expression of \( \text{FGFR4} \) in patients with OSCC recruited from patients with HNSCC in the TCGA database. We observed that the expression of \( \text{FGFR4} \) was significantly higher in cancerous tissues than that in the normal tissue in OSCC (Figure 3B). Koole et al [35] revealed that the \( \text{FGFR4} \) protein was overexpressed in OSCC cells. Shi et al [36] established that \( \text{FGFR4} \) was high expressed in nasopharyngeal carcinoma (NPC) clinical samples and cell lines. The results concluded that high expression of \( \text{FGFR4} \) was associated with poor prognosis of NPC patients. We also observed that \( \text{FGFR4} \) expression was higher in advanced clinical stages (stage III/IV) than stage I/II (Figure 3D). A previous study found that high expression of the \( \text{FGFR4-R388} \) allele was significantly associated with reduced overall survival and with an advanced tumor stage in HNSCC; data supporting our findings is available in the TCGA.

### Table 5: Frequencies of \( \text{FGFR4} \) haplotypes in OSCC patients and control subjects

| Haplotype block | Controls \( n = 2382 \) | Patients \( n = 1910 \) | OR (95% CI) | p Value | AOR (95% CI)\(^a\) | p Value |
|----------------|-----------------|-----------------|-------------|--------|-----------------|--------|
| rs351855 G/A  | rs1966265 A/G   |                 |             |        |                 |        |
| G             | A               | 527 (22.1%)     | 204 (10.7%) | 1.000 (reference) | 1.000 (reference) |
| G             | G               | 737 (30.9%)     | 770 (40.3%) | 2.699 (2.231-3.266) | p<0.001* |
| A             | G               | 413 (17.3%)     | 170 (8.9%)  | 1.063 (0.836-1.353) | p=0.672 |
| A             | A               | 705 (29.7%)     | 766 (40.1%) | 2.807 (2.318-3.398) | p<0.001* |

\(^a\) Adjusting for the effects of betel quid chewing, cigarette smoking and alcohol drinking.

### Table 6: Combined effect of betel quid chewing and \( \text{FGFR4} \) haplotypes on OSCC development

| Betel quid chewing | \( \text{FGFR4} \) haplotype | Controls \( n = 2382 \) | Patients \( n = 1910 \) | AOR (95% CI)\(^b\) | p Value |
|-------------------|-----------------|-----------------|-----------------|-------------------|--------|
| Yes               | A-A             | 124 (5.2%)      | 596 (31.2%)     | 20.863 (16.159-26.937) | p<0.001* |
| Yes               | Others\(^a\)    | 274 (11.5%)     | 938 (49.1%)     | 15.394 (12.446-19.039) | p<0.001* |
| No                | A-A             | 581 (24.4%)     | 170 (8.9%)      | 1.960 (1.560-2.464) | p<0.001* |
| No                | Others\(^a\)    | 1403 (58.9%)    | 206 (10.8%)     | 1.000 (reference)  |        |

\(^a\) Other haplotypes included G-A, G-G, and A-G.

\(^b\) Adjusting for the effects of cigarette smoking and alcohol drinking.

P-values were adjusted for multiple comparisons by applying the Bonferroni correction.
Figure 2: Functional implication and \textit{In silico} profiling of FGFR4 SNP rs351855. (A) Schematic representation of the full-length human FGFR4 protein domain organization. The orange represent the transmembrane that rs351855 was located in this region. (B) Ribbon diagram depicts the transmembrane of rs351855. The blue circles represent amino acids abbreviation and the black circle represents the rs351855 residue change. (C) Mammalian of FGFR4 proteins sequences showed in this alignment. Human \textit{(homo, NM\_002011.4)}, chimp \textit{(Pan troglodytes, NC\_006472.4)}, mouse \textit{(mus, NM\_008011.2)}, rat \textit{(rattus norvegicus, NM\_001109904.1)}, and cow \textit{(bos taurus, NM\_001109904.1)}. (D) Prediction of transmembrane helices in rs351855.
Figure 3: FGFR4 mRNA levels increased in OSCC samples. (A) Different cancer types of FGFR4 mRNA level from The Cancer Genome Atlas (TCGA) Data Portal from Broad GDAC Firehose data portal. (B) The expression of FGFR4 in normal and OSCC from TCGA Data Portal. (C) Relative expression of FGFR4 in 32 pairs of OSCC tumor tissues and their corresponding adjacent non-cancerous tissues. (D) Relative FGFR4 levels were compared according to clinical stage. (E) Relative FGFR4 levels were compared according to tumor T status.
database [23]. In addition, various studies also showed the association between FGFR4 Gly388Arg polymorphism and survival in HNSCC [22-24, 37-41]. Dutra et al. [41] found that Arg388 allele was correlated with lymphatic embolization and disease related premature death in squamous cell carcinoma of the mouth and oropharynx. da Costa Andrade et al. [37] confirmed that the FGFR4 Arg388 allele had a significantly shorter survival in HNSCC. Farnebo et al. [38] illustrated that the FGFR4 Arg388 allele had a significantly longer overall survival in HNSCC. These conflicting evidences on FGFR4 Gly388Arg polymorphism in HNSCC need to be further investigated and clarified the mechanism.

Our study had some limitations. First, our data were obtained from only two medical centers; thus, referral bias might have occurred. Second, the questionnaire information on betel nut chewing, cigarette smoking, and alcohol consumption was reported as “frequent” or “never.” Therefore, we could not comprehensively analyze the amount betel nut, tobacco, and alcohol used, length of use, and history of betel nut chewing, cigarette smoking, and alcohol consumption. Another limitation of our study is functional assay and the mechanism should be elucidated in laboratory and clinically.

In conclusion, the rs351855 polymorphism of FGFR4 has potential predictive significance in OSCC. A combination of betel nut chewing and the FGFR4 T-A haplotype is associated with an increased risk of OSCC. High expression levels of the FGFR4 were significantly associated with a clinical advanced stage. The rs351855 (Gly388Arg) might be used to improve the prediction of clinical prognosis of patients with OSCC.

MATERIALS AND METHODS

Study population

We recruited 955 male patients with OSCC from Chung Shan Medical University Hospital in Taichung, Taiwan, between 2007 and 2016. We selected 1191 healthy male individuals without a history of cancer at any sites to constitute the control group from Taiwan Biobank. Personal information and characteristics were obtained from the participants. Furthermore, demographic characteristics; details of betel quid chewing, tobacco smoking, and alcohol consumption; and medical histories of the participants were recorded. Patients’ medical information, including tumor–nodes–metastasis (TNM) clinical staging, primary tumor size, lymph node involvement, and histologic grade, was obtained from their medical records. The patients were staged clinically at the time of diagnosis according to the TNM staging system of the American Joint Committee on Cancer [42]. The study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (CSMUH No: CS13214-1). Whole-blood specimens from the patients with OSCC and controls were collected in tubes containing ethylene diamine tetra-acetic acid (EDTA), immediately centrifuged, and stored at −80°C.

Determination of genotypes

Genomic DNA was extracted from peripheral blood leukocytes using QIAamp DNA blood mini kits (Qiagen, Valencia, CA, USA) by following the manufacturer’s instructions. We dissolved the extracted DNA in a Tris–EDTA buffer (10 mM Tris, 1 mM EDTA; pH 7.8) and subsequently quantified it by measuring at the absorbance at 260 nm. The final preparation was stored at −20°C and was then used to create templates for polymerase chain reaction (PCR). Allelic discrimination for the FGFR4 SNPs was assessed using the TaqMan assay (ID C_8817791_10 for rs2011077, C_3166614_10 for rs351855, C_11270571_10 for rs7708357, and C_11317464_20 for rs1966265) with an ABI StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Subsequent assessment was performed using SDS version 3.0. The total volume of the TaqMan assay mixture was 10 μL, consisting of 5 μL of Master Mix, 0.25 μL of probes, and 10 ng of genomic DNA. The real-time PCR reaction included an initial denaturation step at 95°C for 10 min, followed by 40 amplification cycles of 95°C for 15 sec and 60°C for 1 min.

Bioinformatics analysis

We used several bioinformatic tools to assess the putative functional relevance of the rs351855 FGFR4 polymorphism. Data from the Pfam 31.0 database were used to identify the rs351855 polymorphism in sequence alignments (template as PDB accession number: 4TYE). We used UCSC Cancer Genomics Browser [43] for analyzing the molecular features of FGFR4. Furthermore, we used the TMHMM transmembrane domain of rs351855 with Server v. 2.0 to predict transmembrane helices in FGFR4.

Statistical analysis

Genotype distributions of the four tagging single nucleotide polymorphisms (tSNPs) were tested for Hardy-Weinberg equilibrium (HWE), which means the allelic distribution between all populations and in our study was not different (p < 0.05). The Mann-Whitney U test and Fisher’s exact test were used to compare differences in the distribution of age and demographic characteristics between the controls and OSCC patients. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of the association between genotypes frequencies and risk plus clinicopathological characteristics were estimated by multiple testing (bonferroni correction), after controlling for other covariates. We estimated the common haplotypes by PHASE version 2.1 [44]. The data were analyzed by
using SAS statistical software (Version 9.4; SAS Institute Inc., Cary, NC).

Author contributions

CHC, MKC and CWL conceived and designed the experiments; MJC and CMY performed the experiments; CYC, PYT and MKC collected the samples; CMY and JTL analyzed the data; CHC, MKC, CWL and SFY wrote the paper.

CONFLICTS OF INTEREST

The authors declared no conflicts of interest.

FUNDING

This study was financially supported by grants from Changhua Christian Hospital (103-CCH-ICO-006) (105-CCH-IRP-055). This study was also supported by Chung Shan Medical University and Changhua Christian Hospital (CSMU-CCH-106-04).

REFERENCES

1. Thiss B, Thiss C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005; 287: 390-402. http://doi.org/10.1016/j.ydbio.2005.09.011.
2. Wescie J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437: 199-213. http://doi.org/10.1042/BJ20101603.
3. Haugsten EM, Wiedlocha A, Olsnes S, Wescie J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010; 8: 1439-52. http://doi.org/10.1158/1541-7786.MCR-10-0168.
4. Tiong KH, Mah LY, Leong CO. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis. 2013; 18: 1447-68. http://doi.org/10.1007/s10495-013-0886-7.
5. Gao L, Feng Z, Li Q, Li L, Chen L, Xiao T. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma. Tumour Biol. 2014; 35: 2997-3002. http://doi.org/10.1007/s13277-013-1386-7.
6. Rezvani M, Wilde J, Vitt P, Mallaparambil B, Grychtol R, Krueger M, Heinzmann A. Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress. Dis Markers. 2013; 35: 633-40. http://doi.org/10.1155/2013/932356.
7. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, Satoh S, Ogawa O, Habuchi T. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008; 123: 2574-9. http://doi.org/10.1002/ijc.23578.
8. Xu W, Li Y, Wang X, Chen B, Wang Y, Liu S, Xu J, Zhao W, Wu J. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Eur J Cancer. 2010; 46: 3332-8. http://doi.org/10.1016/j.ejca.2010.06.017.
9. Sheu MJ, Hsieh MJ, Chiang WL, Yang SF, Lee HL, Lee LM, Yeh CB. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One. 2015; 10: e0122961. http://doi.org/10.1371/journal.pone.0122961.
10. Chen TH, Yang SF, Liu YF, Lin WL, Han CP, Wang PH. Association of fibroblast growth factor receptor 4 genetic polymorphisms with the development of uterine cervical cancer and patient prognosis. Reprod Sci. 2017. http://doi.org/10.1177/1933719117702250.
11. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008; 87: 14-32. http://doi.org/10.1177/154405910808700104.
12. Kao SY, Lim E. An overview of detection and screening of oral cancer in Taiwan. Chin J Dent Res. 2015; 18: 7-12.
13. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol. 2009; 45: 301-8. http://doi.org/10.1016/j.oraloncology.2009.01.004.
14. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg. 2003; 61: 751-8.
15. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995; 24: 450-3.
16. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006; 24: 3747-55. http://doi.org/10.1200/JCO.2005.04.8587.
17. Ezzat S, Zheng L, Winer D, Asa SL. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol. 2006; 20: 2965-75. http://doi.org/10.1210/me.2006-0223.
18. Roidl A, Berger HJ, Kumar S, Bange J, Knayzev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009; 15: 2058-66. http://doi.org/10.1158/1078-0432.CCR-08-0890.
19. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005; 92: 320-7. http://doi.org/10.1038/sj.bjc.6602274.

www.impactjournals.com/oncotarget
20. Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattnier S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, et al. Differential effects of polymorphic alleles of FGFR receptor 4 on colon cancer growth and metastasis. Cancer Res. 2012; 72: 5767-77. http://doi.org/10.1158/0008-5472.CAN-11-3654.

21. Chen L, Lei Z, Ma X, Huang Q, Zhang X, Zhang Y, Hao P, Yang M, Zhao X, Chen J, Liu G, Zheng T. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population. Sci Rep. 2016; 6: 33604. http://doi.org/10.1038/srep33604.

22. Choi KY, Rho YS, Kwon KH, Chung EJ, Kim JH, Park IS, Lee DJ. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma. Cancer Biomark. 2012; 12: 115-24. http://doi.org/10.3233/CBM-130299.

23. Streit S, Bange J, Fichtner A, Ihrlers S, Issing W, Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004; 111: 213-7. http://doi.org/10.1002/ijc.20204.

24. Ansell A, Farnebo L, Grenman R, Roberg K, Thunell LK. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol. 2009; 45: 23-9. http://doi.org/10.1016/j.oraloncology.2008.03.007.

25. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008; 99: 1507-14. http://doi.org/10.1111/j.1349-7006.2008.00863.x.

26. Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing: potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer. 2001; 85: 661-7. http://doi.org/10.1054/bjoc.2001.1920.

27. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK, Lin SC. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol. 2002; 196: 300-6. http://doi.org/10.1002/path.1047.

28. Lin SC, Chen YJ, Kao SY, Hsu MT, Lin CH, Yang SC, Liu TY, Chang KW. Chromosomal changes in betel-associated oral squamous cell carcinomas and their relationship to clinical parameters. Oral Oncol. 2002; 38: 266-73.

29. Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer. 2004; 91: 1551-5. http://doi.org/10.1038/sj.bjc.6602186.

30. Liu CJ, Chang KW, Chao SY, Kwan PC, Chang SM, Yen RW, Wang CY, Wong YK. The molecular markers for prognostic evaluation of areca-associated buccal squamous cell carcinoma. J Oral Pathol Med. 2004; 33: 327-34. http://doi.org/10.1111/j.1600-0714.2004.00922.x.

31. Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, Chang KW. Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer. 2005; 116: 526-35. http://doi.org/10.1002/ijc.21104.

32. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Haring HU, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Res. 2002; 62: 840-7.

33. Morimoto Y, Ozaki T, Ouchiida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003; 98: 2245-50. http://doi.org/10.1002/cncr.11778.

34. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keskioja J, Lehti K. FGFR receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A. 2010; 107: 15786-91. http://doi.org/10.1073/pnas.0914459107.

35. Koole K, van Kempen PM, van Bockel LW, Smets T, van der Klooster Z, Dutman AC, Peeters T, Koole R, van Diest P, van Es RJ, Willems SM. FGFR4 is a potential predictive biomarker in oral and oropharyngeal squamous cell carcinoma. Pathobiology. 2015; 82: 280-9. http://doi.org/10.1159/000439536.

36. Shi S, Li X, You B, Shan Y, Cao X, You Y. High expression of FGFR4 enhances tumor growth and metastasis in nasopharyngeal carcinoma. J Cancer. 2015; 6: 1245-54. http://doi.org/10.7150/jca.12825.

37. da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, SILVA AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol. 2007; 82: 53-7. http://doi.org/10.1016/j. yexmp.2006.05.003.

38. Farnebo L, Tiefenbock K, Ansell A, Thunell LK, Garvin S, Roberg K. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer. 2013; 133: 1994-2003. http://doi.org/10.1002/ijc.28200.

39. Azad AK, Bairati I, Samson E, Cheng D, Mirshams M, Qiu X, Savas S, Waldron J, Wang C, Goldstein D, Xu W, Azad A, Alqawasheh A, Alsalim S, Jabbour S, Valavar K, Garcia J, Maghbooli M, Samsami B, Worthen J, Khatami A, Jafari H, Roushdy M, Khayamian V, Kargaradi J, Khajavi M, Kehagias S, Anagnostaki K, Dabirian M, Khosravi Fard S, Khatami A, Farzaneh F, Bedi FP, et al. Cancer progression and sensitivity to cisplatin and radiation in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2012; 109: 77. http://doi.org/10.1158/0008-5472.CAN-11-3654.
41. Dutra RL, de Carvalho MB, Dos Santos M, Mercante AM, Gazito D, de Cicco R, Tajara EH, Louro ID, da Silva AM, Group G. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One. 2012; 7: e50747. http://doi.org/10.1371/journal.pone.0050747.

42. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-4. http://doi.org/10.1245/s10434-010-0985-4.

43. Goldman M, Craft B, Swatloski T, Cline M, Morozova O, Diekhans M, Haussler D, Zhu J. The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res. 2015; 43: D812-7. http://doi.org/10.1093/nar/gku1073.

44. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21: 263-5. http://doi.org/10.1093/bioinformatics/bth457.